90 related articles for article (PubMed ID: 19362984)
1. Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenström's macroglobulinemia.
Law CL; McEarchern JA; Grewal IS
Clin Lymphoma Myeloma; 2009 Mar; 9(1):90-3. PubMed ID: 19362984
[TBL] [Abstract][Full Text] [Related]
2. CD70 as a therapeutic target in human malignancies.
Grewal IS
Expert Opin Ther Targets; 2008 Mar; 12(3):341-51. PubMed ID: 18269343
[TBL] [Abstract][Full Text] [Related]
3. Novel agents in the treatment of Waldenström's macroglobulinemia.
Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD40 in Waldenström's macroglobulinemia.
Lee M; Advani R
Clin Lymphoma Myeloma; 2009 Mar; 9(1):87-9. PubMed ID: 19362983
[TBL] [Abstract][Full Text] [Related]
5. Targeting CD70 for human therapeutic use.
Boursalian TE; McEarchern JA; Law CL; Grewal IS
Adv Exp Med Biol; 2009; 647():108-19. PubMed ID: 19760069
[TBL] [Abstract][Full Text] [Related]
6. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
[TBL] [Abstract][Full Text] [Related]
7. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
Santos DD; Hatjiharissi E; Tournilhac O; Chemaly MZ; Leleu X; Xu L; Patterson C; Branagan AR; Manning RJ; Ho AW; Hunter ZR; Dimmock EA; Kutok JL; Churchill WH; Castells MC; Tai YT; Anderson KC; Treon SP
Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779
[TBL] [Abstract][Full Text] [Related]
8. Prognosis and treatment of Waldenström's macroglobulinemia.
Louw VJ; Webb MJ
Transfus Apher Sci; 2010 Apr; 42(2):193-7. PubMed ID: 20117052
[TBL] [Abstract][Full Text] [Related]
9. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
Treon SP; Kelliher A; Keele B; Frankel S; Emmanouilides C; Kimby E; Schlossman R; Mitsiades N; Mitsiades C; Preffer F; Anderson KC
Semin Oncol; 2003 Apr; 30(2):248-52. PubMed ID: 12720146
[TBL] [Abstract][Full Text] [Related]
10. CD44/CD70 blockade and anti-CD154/LFA-1 treatment synergistically suppress accelerated rejection and prolong cardiac allograft survival in mice.
Shao W; Yan G; Lin Y; Chen J; Dai H; Wang F; Xi Y; Thorlacius H; Qi Z
Scand J Immunol; 2011 Nov; 74(5):430-7. PubMed ID: 21707692
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus reactivation in a case of Waldenstrom's macroglobulinemia treated with chemotherapy and rituximab despite adefovir prophylaxis.
Khaled Y; Hanbali A
Am J Hematol; 2007 Jul; 82(7):688. PubMed ID: 17366549
[No Abstract] [Full Text] [Related]
12. Current and future therapeutic approach for Waldenström's macroglobulinemia.
Souchet-Cömpain L; Choquet S; Leblond V; Nguyen S
Immunotherapy; 2014; 6(3):333-48. PubMed ID: 24762077
[TBL] [Abstract][Full Text] [Related]
13. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
14. Ofatumumab: another way to target CD20 in Waldenström's macroglobulinaemia?
Buske C
Lancet Haematol; 2017 Jan; 4(1):e4-e5. PubMed ID: 27914970
[No Abstract] [Full Text] [Related]
15. Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis.
Oflazoglu E; Boursalian TE; Zeng W; Edwards AC; Duniho S; McEarchern JA; Law CL; Gerber HP; Grewal IS
J Immunol; 2009 Sep; 183(6):3770-7. PubMed ID: 19710474
[TBL] [Abstract][Full Text] [Related]
16. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
[TBL] [Abstract][Full Text] [Related]
17. Effects of anti-CD70 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease.
Yanagisawa S; Takeichi N; Kaneyama T; Yagita H; Taniguchi S; Kim BS; Koh CS
Brain Res; 2010 Mar; 1317():236-45. PubMed ID: 20045400
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
19. An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
Amin CJ; Rabinowitz I
Clin Lab Haematol; 2005 Jun; 27(3):200-2. PubMed ID: 15938727
[TBL] [Abstract][Full Text] [Related]
20. Blockade of CD70-CD27 interaction inhibits induction of allergic lung inflammation in mice.
Makino F; Ito J; Abe Y; Harada N; Kamachi F; Yagita H; Takahashi K; Okumura K; Akiba H
Am J Respir Cell Mol Biol; 2012 Sep; 47(3):298-305. PubMed ID: 22499851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
